5-fluorouracil, adriamycin, and mitomycin-C (FAM) chemotherapy in advanced adenocarcinoma of the lung: comparison of two dosage schedules

✍ Scribed by W. K. Lam; S. Y. So; T. M. Kung; M. K. Sham; Mary Ip

• Publisher: Springer
• Year: 1987
• Tongue: English
• Weight: 254 KB
• Volume: 19
• Category: Article
• ISSN: 0344-5704
• DOI: 10.1007/bf00252986

✦ Synopsis

Fifty patients with inoperable adenocarcinoma of the lung were randomized in a prospective study to receive either standard doses or high doses of 5-fluorouracil, adriamycin, and mitomycin-C (FAM versus Hi-FAM). The response/stabilization rate was 32% for FAM and 34% for Hi-FAM (P greater than 0.05), and the median survival was 27 weeks for FAM group and 24 weeks for Hi-FAM group (P greater than 0.05). Myelotoxicity was mild in FAM, but moderate to severe in Hi-FAM. It is concluded that Hi-FAM did not yield a higher response rate or median survival compared with FAM, but caused significantly more severe myelotoxicity.